AR and prostate cancer: In vitro studies of castration resistant prostate cancer cell lines displayed mutations of the AR ligand binding domain (HΔY874, TΔA877) that may increase tumor responsiveness to hydrophobic biomolecules including the original AR ligands testosterone and DHT, as well as novel ligands such as β-estradiol that entirely circumvent the tumor dependence on androgens.